All Posts

Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

TGTX BRIUMVI (Ublituximab) approved for MS on 12/28/2022! See the new label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/76...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Last week we saw the MDGL NASH data on Monday and it's up over +300%. This next week we see LOTS of PDUFA events happening to close out...

Summary: Esperion CLEAR outcomes data came out Dec 7 This was a month early and stock did not react well (down 15% on 12/7 and 32% that...

We're winding down to the end of 2022 but still have lots of major readouts left with year. This includes readouts from companies like...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...